Maybe all is not lost in world of life science venture capital. In what amounts to a rare piece of good news for the beleaguered industry, Domain Associates announced Monday that it is establishing a $500 million fund that will be devoted to exclusively to life sciences.

The announcement from Domain, which is based both in San Diego and Princeton, N.J., comes at a time of unprecedented retrenchment for the industry both here and elsewhere. Among Domain’s success stories are San Diego-based companies NuVasive and Orexigen Therapeutics. The former is a medical device company specializing in spinal implants, and the latter is working on an obesity drug.

Here is a statement from Domain’s announcement:

Domain will continue to focus on early stage companies in the drug and device sectors with a meaningful portion of its efforts going towards the diagnostics and instrumentation sectors.

A hat tip goes to Xconomy, for alerting me to this item.


Leave a comment

We expect all commenters to be constructive and civil. We reserve the right to delete comments without explanation. You are welcome to flag comments to us. You are welcome to submit an opinion piece for our editors to review.

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.